20 June 2013
Keywords: novartis, marks, five, glivec, milestone, strong, cml
Article | 15 May 2006
Swiss drug major Novartis says that recent data, marking four and a half years since Gleevec/Glivec (imatinib), its treatment ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
15 May 2006
19 June 2013
© 2013 thepharmaletter.com